Artal Group S.A. Nektar Therapeutics Transaction History

Artal Group S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $3.97 Million - $5.92 Million	-239,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $4.4 Million - $6.12 Million	-261,000 Reduced 52.2%	239,000 $5.54 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $3.38 Million - $7.25 Million	-200,000 Reduced 28.57%	500,000 $9.11 Million
Q2 2019 Aug 09, 2019	SELL	$31.0 - $36.3 $6.2 Million - $7.26 Million	-200,000 Reduced 22.22%	700,000 $24.9 Million
Q1 2019 May 10, 2019	BUY	$31.58 - $46.35 $3.16 Million - $4.64 Million	100,000 Added 12.5%	900,000 $30.2 Million
Q3 2018 Nov 09, 2018	SELL	$46.46 - $68.49 $4.65 Million - $6.85 Million	-100,000 Reduced 11.11%	800,000 $48.8 Million
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $9.25 Million - $20.9 Million	200,000 Added 28.57%	900,000 $43.9 Million
Q1 2018 May 10, 2018	BUY	$57.4 - $108.44 $17.2 Million - $32.5 Million	300,000 Added 75.0%	700,000 $74.4 Million
Q4 2017 Feb 09, 2018	SELL	$23.02 - $60.5 $19.6 Million - $51.4 Million	-850,000 Reduced 68.0%	400,000 $23.9 Million
Q3 2017 Nov 08, 2017	BUY	$17.79 - $24.0 $22.2 Million - $30 Million	1,250,000	1,250,000 $30 Million

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.